XML 36 R25.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Stock-Based Compensation Plans | 12 Months Ended
--- | ---
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract] |
Stock Based Compensation Plans | 16. STOCK-BASED COMPENSATION PLANS In May 2018, the shareholders approved the 2018 Equity Plan which authorizes the issuance of up to 9,000,000 shares of CVB’s common stock for eligible participants, which include all of the Company’s employees, officers, and directors, and expires in 2028. The plan authorizes the issuance of a variety of types of equity awards, which include incentive stock options, non-qualified stock options, restricted stock awards (“RSAs”), restricted stock units (“RSUs”), and other stock-based awards, including performance-based restricted stock units ("PRSUs"). The 2018 Equity Plan replaced the 2008 Equity Incentive Plan. No further grants will be made under the 2008 Equity Incentive Plan, but shares may continue to be issued under such plan pursuant to grants previously made. As of December 31, 2023, we have 1,546,125 outstanding options, unvested RSAs, RSUs and PRSUs under our Equity Plans. Stock Options The Company expensed $384,000, $273,000, and $220,000, for the years ended December 31, 2023, 2022 and 2021, respectively. The estimated fair value of the options granted during 2023 and prior years was calculated using the Black-Scholes options pricing model. There were 107,000, 66,000 and 64,500 options granted during 2023, 2022 and 2021, respectively. The options will vest, in equal installments, over a five-year period. The fair value of each stock option granted in 2023, 2022 and 2021, was estimated on the date of grant using the following weighted-average assumptions.
|  | Year Ended December 31, |
|  | 2023 |  |  | 2022 |  |  | 2021 |
Dividend yield |  |  | 9.4 | % |  |  | 3.0 | % |  |  | 3.6 | %
Volatility |  |  | 28.0 | % |  |  | 27.9 | % |  |  | 29.6 | %
Risk-free interest rate |  |  | 3.7 | % |  |  | 1.2 | % |  |  | 0.4 | %
Expected life |  | 10.0 years |  |  | 10.0 years |  |  | 5.5 years |
Weighted average grant date fair value |  | $ | 11.09 |  |  | $ | 8.60 |  |  | $ | 3.45 |
The expected volatility is solely based on the daily historical stock price volatility over the expected option life. The expected life of options granted is derived from the output of the option valuation model and represents the period of time an optionee will hold an option before exercising it. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury five-year constant maturity yield curve in effect at the time of the grant. In connection with the adoption of ASU 2016-09 in 2017, the Company elected to account for forfeitures as they occur, rather than to estimate forfeitures over the vesting period. The following table presents option activity under the Company’s stock option plans as of and for the year ended December 31, 2023.
|  | Number of Stock Options Outstanding |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Term |  |  | Aggregate Intrinsic Value |
|  | (In thousands) |  |  |  |  |  | (In years) |  |  | (In thousands) |
Outstanding at January 1, 2023 |  |  | 318 |  |  | $ | 19.25 |  |  |  |  |  |  |
Granted |  |  | 107 |  |  |  | 23.95 |  |  |  |  |  |  |
Exercised |  |  | (13 | ) |  |  | 16.92 |  |  |  |  |  |  |
Forfeited or expired |  |  | (26 | ) |  |  | 21.39 |  |  |  |  |  |  |
Outstanding at December 31, 2023 |  |  | 386 |  |  | $ | 20.50 |  |  |  | 6.78 |  |  | $ | 456 |
Vested or expected to vest at December 31, 2023 |  |  | 386 |  |  | $ | 20.50 |  |  |  | 6.78 |  |  | $ | 456 |
Exercisable at December 31, 2023 |  |  | 201 |  |  | $ | 18.67 |  |  |  | 5.32 |  |  | $ | 398 |
The total intrinsic value of options exercised during the years ended December 31, 2023, 2022 and 2021 was $53,000, $1.0 million and $262,000, respectively. As of December 31, 2023, there was a total of $1.3 million in unrecognized compensation cost related to nonvested options granted under the Plan. That cost is expected to be recognized over a weighted-average period of approximately 3.8 years. The total fair value of options vested was $267,000, $203,000 and $258,000 during 2023, 2022 and 2021, respectively. Cash received from stock option exercises was $210,000, $1.9 million and $1.3 million, in 2023, 2022 and 2021, respectively. At December 31, 2023, options for the purchase of 386,350 shares of CVB’s common stock were outstanding under the above plans, of which options to purchase 200,550 shares were exercisable at prices ranging from $14.61 to $24.83. The Company has a policy of issuing new shares to satisfy share option exercises. Restricted Stock Awards, Restricted Stock Units and Performance-Based Restricted Stock Units The Company granted 484,000, 674,961 and 394,884 restricted stock awards during 2023, 2022 and 2021 respectively. The weighted average grant date fair value of RSAs, RSUs and PRSUs granted in 2023, 2022 and 2021 was $22.44 per share, $22.82 per share and $20.43 per share, respectively. These awards will vest, in equal installments, over a period of approximately one to five years. Compensation cost is recognized over the requisite service period, which is approximately one to five years, and amounted to $9.1 million, $7.6 million and $5.0 million during t he years ended December 31, 2023, 2022 and 2021, respectively. Total unrecognized compensation cost related to RSAs and PRSUs was $16.7 million at December 31, 2023. The table below summarizes activity related to the Company’s non-vested RSAs and PRSUs for the year ended December 31, 2023.
|  | Shares |  |  | Weighted Average Fair Value |
|  | (In thousands) |  |  |  |
Nonvested at January 1, 2023 |  |  | 1,069 |  |  | $ | 21.37 |
Granted |  |  | 484 |  |  |  | 22.44 |
Vested |  |  | (364 | ) |  |  | 20.95 |
Forfeited |  |  | (32 | ) |  |  | 22.57 |
Nonvested at December 31, 2023 |  |  | 1,157 |  | (1) | $ | 21.93 |
(1) Includes 189,042 PRSUs. There are no restricted stock units outstanding. Under the 2018 Equity Incentive Plan, 6,019,107 shares of common stock were available for the granting of future stock-based awards as of December 31, 2023.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration